311 - VALVULAR HEART DISEASE: MAKING SENSE OF A CHANGING LANDSCAPE AND EVOLVING GUIDELINES

Saturday, October 25, 2025

10:00am - 11:00am ET

Room:202

Co-Chair(s)

RN

Rashmi Nedadur, MD MSc

Cardiac Surgeon
London Health Sciences Center
Western University
Christopher White, MD PhD FRCSC (he/him/his)

Cardiac Surgeon
CSCS
Dalhousie University

Panelist(s)

RC

Renzo Cecere, MD, FRCSC

Principal Investigator

Special Invited Guest(s)

Michael Borger

University of Leipzig
Marc Pelletier

McGill University

Session Description: Valvular heart disease is undergoing a rapid transformation, driven by evolving evidence, updated guidelines, and expanding interventional options. This session brings together international thought leaders to distill the most critical updates from the 2025 guidelines and highlight key clinical trials reshaping the management of structural valve disease. A moderated panel will explore the implications for surgical practice and heart team collaboration in this dynamic landscape.

Presentations:

What’s New and What Matters: 2025 Valvular Heart Disease Guideline Updates for Every Clinician – Dr. Michael Borger

Structural Valve Disease: Interventions and Trials – A Year in Review – Dr. Marc Pelletier

Learning Objectives:

At the end of this session participants will be able to:

Summarize the major updates in the 2025 valvular heart disease guidelines, with an emphasis on practical implications for surgical and transcatheter decision-making;
Review landmark clinical trials and innovations in structural valve interventions over the past year, including their impact on treatment algorithms; and
Discuss the evolving role of the multidisciplinary heart team, particularly in the context of patient selection, timing of intervention, and emerging technologies.